Chapter: Malaria and Other Parasitic Infections

1. Evaluate patients with the following parasitic infections by microbiological features, clinical signs, and worldwide prevalence: malaria, cryptosporidiosis, cysticercosis, giardiasis, toxoplasmosis, amebiasis.
2. Distinguish the effect climate change will have on the epidemiology of common parasitic infections and how it affects the role of health care providers.
3. Design recommendations for pharmacologic and nonpharmacologic prophylaxis against parasitic infections.
4. Develop recommendations for patients who need prophylaxis or treatment for common parasitic infections without imposing bias or stigma. 

Chapter: Travel Medicine

1. Account for changes in pharmacotherapy due to evolution in the field of travel medicine.
2. Justify the role of the pharmacist in travel medicine.
3. Classify common types of infections associated with global travel.
4. Evaluate current resources for infectious diseases in travel medicine.
5. Design treatment regimen and consult for a patient (e.g., pre-travel, during travel, and posttravel). 6. Develop a plan for post-travel monitoring. 

Chapter: Tuberculosis and Resistance

1. Distinguish between the types of drug-resistant tuberculosis.
2. Evaluate differences in current guidelines of drug therapy recommendations for the management of drug-resistant tuberculosis.
3. Design an optimal treatment regimen for drug-resistant tuberculosis in different patientspecific clinical scenarios.
4. Develop a monitoring plan to assess medication effectiveness and toxicity in patients receiving treatment for drug-resistant tuberculosis.  

Chapter: Antimicrobial Stewardship and Resistance in Low- and Middle-Income Countries

1. Design an antimicrobial stewardship program specific to a low- to middle-income country (LMIC).
2. Implement an antimicrobial stewardship program appropriate for an LMIC.
3. Evaluate strategies to combat antimicrobial resistance. 

Chapter: HIV Response in Low- and Middle-Income Countries

1. Devise strategies to address inequalities in the management of HIV in low- to middle-income countries (LMIC).
2. Design a patient-centered plan for the management of HIV in adults in alignment with the WHO guidelines.
3. Distinguish differences in treatment and prevention guidelines for HIV in LMIC compared with high-income countries.
4. Develop a monitoring plan to assess the efficacy, safety, and adherence to antiretroviral therapy in patients with HIV in LMIC.
5. Evaluate long-acting injectables and investigational agents to determine their role in the treatment and prevention of HIV. 

Chapter: Health Equity in Infectious Diseases

1. Distinguish among the terms health equity and health disparities.
2. Evaluate the impact of health disparities on patient health outcomes.
3. Evaluate the association between social determinants of health and patient health outcomes.
4. Determine how health inequities affect the distribution of COVID-19.
5. Evaluate social risk factors that contribute to pharmacoequity.
6. Develop strategies to close the pharmacoequity gap. 

Interactive Case: Re-introduction of Anti-TB Therapy in Patients with Hepatic Toxicity

1. Estimate a patient’s risk of drug-induced hepatotoxicity.
2. Analyze anti-tuberculosis (TB) medications that can cause hepatotoxicity.
3. Construct a pharmacotherapeutic plan for a patient who is being reintroduced to a hepatotoxic anti-TB medication.
4. Assess potential challenges associated with anti-TB medications that cause hepatotoxicity and efficacy of care. 

Recorded Webcast: Drug Acquisition and Allocation in Resource-Limited Settings

1. Evaluate the functions of the WHO Essential Medicines List.
2. Assess the current state of essential medicines around the world, particularly in low- to middle-income countries (LMIC).
3. Analyze current areas of inefficiencies and how they affect patient care.
4. Justify recommendations on best practices and real-life examples to ensure availability, accountability, and affordability of medications.